- Net income reached $3.9M ($0.05 diluted EPS) due to non-cash fair value adjustments, against an operating loss of $6.3M
- Cash and equivalents stood at $9.9M as of Sept 30, 2026, funding operations only through mid-Q1 2027
- NDA submitted to FDA for CNM-Au8 in ALS; Phase 3 RESTORE-ALS trial planned for 2027
Why is $CLNN moving today? · SEC 8-K archive
$CLNN SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $CLNN: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $CLNN filing catalyst
Why did $CLNN trigger an AI stock catalyst alert?
$CLNN triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.0/10). Headline: Clene Reports Q3 Net Income Driven by Non-Cash Gains, Cash Runway Extends Only to Mid-Q1 2027. Key points: - Net income reached $3.9M ($0.05 diluted EPS) due to non-cash fair value adjustments, against an operating loss of $6.3M - Cash and equivalents stood at $9.9M as of Sept 30, 2026, funding operations only through mid-Q1 2027 - NDA submitted to FDA for CNM-Au8 in ALS; Phase 3 RESTORE-ALS trial planned for 2027
How did $CLNN stock react after the SEC filing?
After the SEC 8-K for $CLNN, observed market reaction: T0 price $3.77. Past moves do not guarantee future results.
Where can I get real-time $CLNN SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $CLNN via Telegram and the VIP Web Terminal from €10/month.